EUCTR2019-001554-25-NL进行中(未招募)1 期
Adalimumab dose optimization in rheumatoid arthritis using therapeuticdrug monitoring (ADDORA): multi-center open label randomized controlledtrail - ADalimumab Dose Optimization in Rheumatoid Arthritis using (ADDORA)
Reade0 个研究点目标入组 267 人开始时间: 2019年10月29日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中(未招募)
- 发起方
- 入组人数
- 267
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •-rheumatoid arthritis patient, according to ACR 1987 or ACR/EULAR 2010 criteria
- •- adalimumab < 16 weeks at registered dose of 40mg every other week
- •-who has agreed to participate (written informed consent);
- •-age 16 years or older.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 167
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 100
排除标准
- •-Life expectancy shorter than follow-up period of the study;
- •-Other disease that might flare if adalimumab is tapered like psoriasis,
- •inflammatory bowel disease.
研究者
相似试验
招募中
不适用
Adalimumab dose optimisation in rheumatoid arthritis using therapeutic drug monitoring (ADDORA): multi-centre open label randomised controlled trailrheumatoid arthritisNL-OMON47985Jan van Breemen Instituut267
招募中
不适用
Adalimumab drug optimisation in rheumatoid arthritis using therapeutic drug monitoring (ADDORA): multi-centre open label randomised controlled trailRheumatoid arthritisNL-OMON26185Reade Rheumatology Research Institute267
进行中(未招募)
1 期
Adalimumab in rheumatoid arthritis. An investigation of changes in disease activity and course of joint destruction by use of 3 Tesla Whole-Body MRI, dedicated 3 Tesla MRI and CT of the hand, and soluble biomarkers.Whole-Body MRI in Rheumatoid Arthritis Protocol (WRAP)Reumatoid artritisMedDRA version: 12.1Level: LLTClassification code 10003268Term: Arthritis rheumatoidEUCTR2009-014394-41-DKHvidovre Hospital
招募中
4 期
Adalimumab Drug Optimisation in Rheumatoid Arthritis Using Therapeutic Drug MonitoringRheumatoid ArthritisNCT04194827Reade Rheumatology Research Institute267
已完成
4 期
Efficacy of HUMIRA in Subjects With Active Rheumatoid ArthritisRheumatoid ArthritisNCT00234897Abbott1,938
